M. Postow
Oncology · 2012–2018
A researcher in the Science corpus: 18 papers; trusts 3 researchers and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Oncology — 259 citations into it; #1,421 of 1,698 by trust here, #32 by citations
- Immunology — 144 citations into it
- Molecular Biology — 127 citations into it
Whom M. Postow trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts M. Postow overall
Papers from M. Postow's perspective
Ordered by how strongly the researchers M. Postow trusts endorse each paper. Same corpus, a different order for every researcher.
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
- The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
- Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. (Science)
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (New England Journal of Medicine)
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (Clinical Cancer Research)
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised,… (The Lancet Oncology)
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients (Nature)
Their papers
- Genetic basis for clinical response to CTLA-4 blockade in melanoma. (2014) — 3,876 citations
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. (2014) — 1,629 citations
- Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma (2015) — 4,132 citations
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (2015) — 2,625 citations
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. (2015) — 926 citations
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (2017) — 3,400 citations
- Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade (2018) — 3,832 citations
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain (2018) — 1,115 citations
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response (2017) — 1,506 citations
- OncoKB: A Precision Oncology Knowledge Base (2017) — 2,318 citations
- Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. (2017) — 1,030 citations
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. (2016) — 758 citations
- Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma (2016) — 835 citations
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. (2016) — 641 citations
- Immune Checkpoint Blockade in Cancer Therapy. (2015) — 2,369 citations
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. (2015) — 935 citations
- Safety and clinical activity of combined PD-1 (nivolumab) and CTLA-4 (ipilimumab) blockade in advanced melanoma patients (2013) — 3,871 citations
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma (2012) — 1,966 citations